PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value
对生命科学的第二项外部投资巩固了先前宣布的利用大量现金状况为股东创造额外价值的战略
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FDA). PharmaCyte's investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position.
Pharmacyte Biotech, Inc.（纳斯达克股票代码：PMCB）（“PharmacYTE” 或 “公司”）今天宣布向MyMD Pharmicals, Inc.（纳斯达克股票代码：MYMD）（“myMD”）投资700万美元，这是一家临床阶段的生物制药公司，致力于开发针对年龄相关疾病、自身免疫和炎症性疾病的新疗法。MyMD 公布了其主要产品 MYMD-1 治疗肌肉减少症的 40 名患者 2 期临床试验的阳性数据，并正在与美国食品药品监督管理局 (FDA) 磋商，推进其临床项目。PharmacYTE对外部开发技术的投资巩固了其谨慎运用其约6500万美元（截至2024年3月31日）现金状况的战略。